The big pharmacy benefit managers prioritize profits over everything, operating in an opaque industry where they can manipulate prices without accountability.

The big three pharmacy benefit managers will not disclose their pricing structures, making it impossible for clients to know if they are being charged fairly.

Insurance companies and pharmacy benefit managers (PBMs) often dictate which medications are authorized, sometimes requiring patients to try cheaper alternatives first, regardless of their effectiveness.

Pharmacy benefit managers often prevent access to cheaper biosimilars like YUSIMRY because they do not receive rebates on them, prioritizing profit over patient savings.

Medical billing is a complex process involving numerous steps to ensure healthcare providers get paid by insurance companies, and submitting claims correctly is particularly challenging.

The big three PBMs are not reimbursing local pharmacies adequately, causing many to go out of business, which is detrimental to community healthcare.

By analyzing our prescription drug costs, I discovered that we spent $169,000 with a pharmacy benefit manager, while it would have only cost $19,000 through Cost Plus Drugs.

Cost Plus Drugs provides a transparent price list for over 2,500 drugs, contrasting sharply with the lack of transparency from major pharmacy benefit managers.

Big pharma is a business that often prioritizes keeping drugs out of generic status to maintain high prices, which can hinder the discovery of new drugs.